Please use this identifier to cite or link to this item:
https://wslhd.intersearch.com.au/wslhdjspui/handle/1/7095
Title: | Screening for obstructive sleep apnoea in post-treatment cancer patients |
Authors: | Subramanian, Harini;Fuchsova, Veronika;Elder, Elisabeth B. B.;Brand, Alison H.;Howle, Julie R.;deFazio, Anna;Mann, Graham J.;Amis, Terence C.;Kairaitis, Kristina |
WSLHD Author: | Subramanian, Harin;Fuchsova, Veronika;Elder, Elisabeth B.;Brand, Alison H.;Howle, Julie R.;deFazio, Anna;Mann, Graham J.;Amis, Terence C.;Kairaitis, Kristina |
Subjects: | Oncology |
Issue Date: | 2023 |
Citation: | Cancer Reports. 6(3):e1740, 2023 Mar |
Abstract: | BACKGROUND AND AIMS: For cancer patients, comorbid obstructive sleep apnea (OSA) poses additional risk to their surgical/anaesthetic outcomes, quality of life, and survival. However, OSA screening is not well-established in oncology settings. We tested two screening tools (STOP-Bang questionnaire [SBQ] and the at-home monitoring device, ApneaLink TMAir), for predicting polysomnography (PSG) confirmed OSA in post-treatment cancer patients. METHODS: Breast (n = 56), endometrial (n = 37) and melanoma patients (n = 50) were recruited from follow-up clinics at Westmead Hospital (Sydney, Australia). All underwent overnight PSG, 137 completed SBQ, and 99 completed ApneaLink TMAir. Positive (PPV) and negative (NPV) predictive values for PSG-determined moderate-to-severe OSA and severe OSA, were calculated using an SBQ threshold >=3 au and ApneaLink TMAir apnoea-hypopnea index thresholds of >=10, >=15 and >=30 events/h. RESULTS: Both SBQ and ApneaLink TMAir had high NPVs (92.7% and 85.2%-95.6% respectively) for severe OSA, but NPVs were lower for moderate-to-severe OSA (69.1% and 59.1%-75.5%, respectively). PPV for both tools were relatively low (all <73%). Combining both tools did not improve screening performance.CONCLUSIONS: These screening tools may help identify cancer patients without severe OSA, but both are limited in identifying those with moderate-to-severe or severe OSA. PSG remains optimal for adequately identifying and managing comorbid OSA in cancer patients. |
URI: | https://wslhd.intersearch.com.au/wslhdjspui/handle/1/7095 |
DOI: | https://dx.doi.org/10.1002/cnr2.1740 |
Journal: | Cancer Reports |
Type: | Journal Article |
Study or Trial: | Cohort Analysis Controlled Study Major Clinical Study |
Department: | Gynaecological Oncology Respiratory and Sleep Medicine Surgery Gynaecological Oncology |
Facility: | Westmead Blacktown Auburn |
Keywords: | Early Detection of Cancer Sleep Apnea, Obstructive Melanoma |
Appears in Collections: | Blacktown Mount Druitt Hospital |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Subramanian-2023-Screening for obstructive sle.pdf | 1.59 MB | Adobe PDF | View/Open |
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.